Insider Selling: Outset Medical (NASDAQ:OM) General Counsel Sells $11,554.48 in Stock

Outset Medical, Inc. (NASDAQ:OM) General Counsel John Brottem sold 2,632 shares of Outset Medical stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $4.39, for a total value of $11,554.48. Following the transaction, the general counsel directly owned 87,475 shares in the company, valued at approximately $384,015.25. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Price Performance

Outset Medical stock traded down $0.33 during mid-day trading on Tuesday, hitting $4.18. The company’s stock had a trading volume of 143,860 shares, compared to its average volume of 407,222. The stock has a market capitalization of $78.57 million, a P/E ratio of -1.02 and a beta of 1.96. Outset Medical, Inc. has a twelve month low of $3.00 and a twelve month high of $16.16. The stock’s fifty day moving average price is $4.58 and its two-hundred day moving average price is $4.24. The company has a quick ratio of 4.11, a current ratio of 5.19 and a debt-to-equity ratio of 1.03.

Outset Medical (NASDAQ:OM) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). The firm had revenue of $31.64 million for the quarter, compared to analysts’ expectations of $28.97 million. Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. Research analysts forecast that Outset Medical, Inc. will post -3.9 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on OM. TD Cowen restated a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. Weiss Ratings upgraded Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Finally, Wall Street Zen raised Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of OM. JPMorgan Chase & Co. grew its holdings in Outset Medical by 662.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,452 shares of the company’s stock valued at $162,000 after buying an additional 7,344 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of Outset Medical in the second quarter valued at approximately $34,000. Rhumbline Advisers acquired a new stake in shares of Outset Medical in the second quarter worth $499,000. New York State Common Retirement Fund bought a new position in Outset Medical during the second quarter worth $108,000. Finally, Quantbot Technologies LP bought a new position in Outset Medical during the second quarter worth $152,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.